Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Victoria Speed

Showing results (11-20 of 29) with videos related to

Pageof 3
Sort By:
Emergency Medicine Journal : EMJ|July 26, 2024
King's lower limb immobilisation VTE risk assessment tool (K4 score) in conservatively treated ambulatory patients: a 2-year reviewElizabeth Marrinan, Victoria Speed, Gerard Giron, et al.
Thrombosis and Haemostasis|October 17, 2023
Factor Xa Inhibitor Plasma Concentrations and Clinical Outcomes in Patients Weighing ≤50 kg-Experience from Four UK CentersVictoria Speed, Rachel Clapham, John Bartoli-Abdou, et al.
British Journal of Haematology|August 6, 2021
Rivaroxaban for the treatment of superficial vein thrombosis, experience at King's College HospitalRachel E Clapham, Victoria Speed, Julia Czuprynska, et al.
Research and Practice in Thrombosis and Haemostasis|November 3, 2022
Pooled Analysis of Rivaroxaban therapy for acute venous thromboembolism in FIRST registry, SWIVTER and DRESDEN NOAC registryStephanie Müller, Luise Tittl, Victoria Speed, et al.
British Journal of Clinical Pharmacology|December 17, 2025
Trends and variation in the use of andexanet alfa for the reversal of direct oral anticoagulants in NHS trusts in EnglandLouis Fisher, Richard Buka, Rosalind Byrne, et al.
BJGP Open|February 1, 2024
Safety of direct-acting oral anticoagulant (DOAC) prescribing: OpenSAFELY-TPP analysis of 20.5 million adults' electronic health recordsKaren Homan, Rachel Seeley, Louis Fisher, et al.
Thrombosis Research|August 24, 2024
Can edoxaban be used at extremes of bodyweight and in patients with a creatinine clearance ≥95 ml/min? - A population pharmacokinetic analysisRachel E Clapham, Victoria Speed, Rosalind Byrne, et al.
BMJ Medicine|December 15, 2025
Opioid prescribing to people on orthopaedic waiting lists during the covid-19 pandemic in England: retrospective cohort study using linked electronic health record data in OpenSAFELY-TPPRose Higgins, Rebecca M Smith, Iain Dillingham, et al.
Journal of Thrombosis and Haemostasis : JTH|June 9, 2020
Fixed dose rivaroxaban can be used in extremes of bodyweight: A population pharmacokinetic analysisVictoria Speed, Bruce Green, Lara N Roberts, et al.
The Lancet. Public Health|June 28, 2024
Changes in opioid prescribing during the COVID-19 pandemic in England: an interrupted time-series analysis in the OpenSAFELY-TTP cohortAndrea L Schaffer, Colm D Andrews, Andrew D Brown, et al.
Pageof 3

Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
Emergency Medicine Journal : EMJ|July 26, 2024
King's lower limb immobilisation VTE risk assessment tool (K4 score) in conservatively treated ambulatory patients: a 2-year reviewElizabeth Marrinan, Victoria Speed, Gerard Giron, et al.
Thrombosis and Haemostasis|October 17, 2023
Factor Xa Inhibitor Plasma Concentrations and Clinical Outcomes in Patients Weighing ≤50 kg-Experience from Four UK CentersVictoria Speed, Rachel Clapham, John Bartoli-Abdou, et al.
British Journal of Haematology|August 6, 2021
Rivaroxaban for the treatment of superficial vein thrombosis, experience at King's College HospitalRachel E Clapham, Victoria Speed, Julia Czuprynska, et al.
Research and Practice in Thrombosis and Haemostasis|November 3, 2022
Pooled Analysis of Rivaroxaban therapy for acute venous thromboembolism in FIRST registry, SWIVTER and DRESDEN NOAC registryStephanie Müller, Luise Tittl, Victoria Speed, et al.
British Journal of Clinical Pharmacology|December 17, 2025
Trends and variation in the use of andexanet alfa for the reversal of direct oral anticoagulants in NHS trusts in EnglandLouis Fisher, Richard Buka, Rosalind Byrne, et al.
BJGP Open|February 1, 2024
Safety of direct-acting oral anticoagulant (DOAC) prescribing: OpenSAFELY-TPP analysis of 20.5 million adults' electronic health recordsKaren Homan, Rachel Seeley, Louis Fisher, et al.
Thrombosis Research|August 24, 2024
Can edoxaban be used at extremes of bodyweight and in patients with a creatinine clearance ≥95 ml/min? - A population pharmacokinetic analysisRachel E Clapham, Victoria Speed, Rosalind Byrne, et al.
BMJ Medicine|December 15, 2025
Opioid prescribing to people on orthopaedic waiting lists during the covid-19 pandemic in England: retrospective cohort study using linked electronic health record data in OpenSAFELY-TPPRose Higgins, Rebecca M Smith, Iain Dillingham, et al.
Journal of Thrombosis and Haemostasis : JTH|June 9, 2020
Fixed dose rivaroxaban can be used in extremes of bodyweight: A population pharmacokinetic analysisVictoria Speed, Bruce Green, Lara N Roberts, et al.
The Lancet. Public Health|June 28, 2024
Changes in opioid prescribing during the COVID-19 pandemic in England: an interrupted time-series analysis in the OpenSAFELY-TTP cohortAndrea L Schaffer, Colm D Andrews, Andrew D Brown, et al.
Pageof 3